Wednesday, April 24, 2024
4/24/2024
PROJECT SUMMARY/ABSTRACT Noncoding ribonucleic acid molecules called microRNAs (miRNAs) have recently emerged as important biological regulators that suppress the expression of target genes via messenger RNA degradation or translational repression. Since miRNAs can regulate gene expression, there is intense interest in utilizing these molecules as tools to halt disease progression. Unfortunately, naked miRNAs are not suitable for clinical use due to their poor stability, limited circulation half---life, and inability to enter cells. Accordingly, researchers have begun to incorporate miRNAs into nanocarriers to facilitate their in vivo delivery. While some progress has been made, there is substantial room for improvement, evidenced by the fact that only a single miRNA nanocarrier has entered clinical trials. This lack of clinical translation indicates there is an urgent need for mechanistic studies to elucidate the underlying principles that dictate the interactions between miRNA nanocarriers and biological systems. We aim to address this need by capitalizing on our unique expertise in nanoparticle design, which includes experience with both miRNA nanocarriers and targeted nanoparticle systems. More specifically, we will elucidate how the physical and chemical properties of miRNA nanocarriers influence five specific outcomes related to the challenges associated with in vivo miRNA delivery. These include: stability and nuclease resistance, cell uptake and intracellular trafficking, gene regulation potency, biodistribution, and ability to halt progression of diseases including breast cancer and osteoporosis. By studying these five outcomes, we can increase understanding of the effects of miRNA nanocarriers on the body, as well as the effects of the body on miRNA nanocarriers. This will enable us to establish a set of design rules that govern the interactions between miRNA nanocarriers and biological systems and which can be applied in the de novo synthesis of miRNA nanocarriers to maximize their site---specific delivery and efficacy. Over the next five years we will focus explicitly on studying how incorporating targeting agents into miRNA nanocarriers influences the five aforementioned outcomes. By comparing different types of targeting agents (e.g., antibodies or proteins) we can increase knowledge of the mechanisms of nanoparticle interactions with cell surface receptors and the impact they have on signal transduction. We hypothesize that targeting agents can not only promote cell binding, but also manipulate signaling cascades via receptor---mediated processes. If this hypothesis is correct, combining miRNA delivery with targeting agent---mediated signal cascade manipulation may have synergistic effects on diseased cells. Importantly, in the future we will expand our studies to investigate other features of miRNA nanocarriers such as size, shape, and stiffness. This will enable us to distinguish how the nanocarrier itself influences various biological outcomes. This important information will enable creation of accurate design rules that will facilitate more efficient clinical translation of new miRNA nanocarriers for disease intervention.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
